Caralluma Extract powder

• Product Detail

Product name	Caralluma Extract powder
Latin Name	Caralluma fimbriata
Active ingredients	glycosides and saponins
synonyms	C. Fimbriate, Caraluma, Caralluma ascendens, Caralluma Cactus, Caralluma Extract, Caralluma fimbriata, Caralluma Fimbriata Extract, Caraluma Pregnane Glycosides, Extrait de Caralluma, Extrait de Caralluma Fimbriata, Kallimudayan, Karallamu, Kullee Mooliyan, Makad Shenguli, Ranshabar, Shindala Makadi, Wild Succulent Cactus, Yugmaphallottama.
Appearance	Light yellow fine powder
Part used	Stem & Leaf
Specification	10:1,20;1
Dosage	500-1000mg daily
Main benefits	weight loss
Applied industries	Medicine, food additive, dietary supplement, sports nutrition

What is Caralluma?

Caralluma fimbriata is a succulent plant in the family Apocynaceae. It has been eaten in rural India for centuries, raw, as a vegetable with spices, or preserved in chutneys and pickles, and is often found as a roadside shrub or boundary marker.

It has been used as a portable food and thirst quencher for hunting. It is also used for its purported ability to suppress hunger and appetite and enhance stamina. It is believed to have an effect on the appetite control centre of the brain. Tribesmen on a day's hunt will often only pack some Caralluma fimbriata to sustain themselves and hence it is commonly known as "famine food" in India.

Chemical constituents of Caralluma Extract powder

The key phytochemical constituents of the herb are pregnane glycosides, flavone glycosides, megastigmane glycosides, and saponins.

Benefits of taking Caralluma Extract powder supplements:

At present is mainly used for weight loss.

Some study support for weight loss.

> Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. (Division of Nutrition, Institute of Population Health and Clinical Research, St John's National Academy of Health Sciences, India. )

Abstract

Caralluma fimbriata is an edible cactus, used by tribal Indians to suppress hunger and enhance endurance. The effect of Caralluma extract was assessed in overweight individuals by a placebo controlled randomized trial. Fifty adult men and women (25-60 years) with a body mass index (BMI) greater than 25 kg/m2 were randomly assigned into a placebo or experimental group; the latter received 1 g of Caralluma extract per day for 60 days. All subjects were given standard advice regarding a weight reducing diet and physical activity. At the end of 30 and 60 days of intervention, blood glucose and lipids, anthropometric measurements, dietary intake and assessment of appetite was performed. Waist circumference and hunger levels over the observation period showed a significant decline in the experimental group when compared to the placebo group. While there was a trend towards a greater decrease in body weight, body mass index, hip circumference, body fat and energy intake between assessment time points in the experimental group, these were not significantly different between experimental and placebo groups. Caralluma extract appears to suppress appetite, and reduce waist circumference when compared to placebo over a 2 month period.

> A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.

Source

Biomedical and Lifestyle Diseases (BioLED) Unit, College of Health and Biomedicine, Victoria University, Melbourne, Victoria 3021, Australia.

Abstract

OBJECTIVES:

Central obesity is a key component of metabolic syndrome and it is often associated with other risk factors such as dyslipidemia, elevated plasma glucose levels and elevated blood pressure (BP). In this pilot study, the effect of Caralluma fimbriata (an edible succulent) extract in combination with controlled dietary intake and physical activity on these risk factors was assessed in overweight and obese Australian subjects.

DESIGN:

This was a randomised, double blind placebo controlled clinical trial. Forty-three adults aged 29-59 years were recruited. The eligibility criteria included a Body Mass Index (BMI) >25 kg/m(2), or a waist circumference >94 cm (male), >80 cm (female). Thirty-three participants completed the 12-week study at Victoria University Nutritional Therapy Clinic. Participants were randomly assigned into two groups. C. fimbriata extract and placebo were orally administered as 500 mg capsules twice daily (1 g/day) and dietary intake and exercise were monitored weekly.

RESULTS:

The results of thirty-three participants (experimental group, n = 17; placebo group n = 16) were analysed. The primary outcome measure was the decline in waist circumference. By week 9, the experimental group had lost 5.7 cm, compared to only 2.8 cm loss in the placebo group (Difference: -2.890; 95% CI; -5.802 to 0.023). Post intervention, the experimental group had lost 6.5 cm compared to 2.6 cm loss in the placebo group (Difference: -3.847; 95% CI; -7.466 to 0.228). Waist to hip ratio (WHR) also improved significantly after 12 weeks intervention in the experimental group, with a total reduction of 0.03 being recorded compared to 0.01 increase in the placebo group (Difference: -0.033; 95% CI; -0.064 to -0.002). There was also a significant decline in the palatability (visual appeal, smell, taste) of the test meal and sodium intake in the experimental group at week 12 (p < 0.05). In addition a significant reduction in body weight, BMI, hip circumference, systolic BP, HR, triglyceride levels, total fat and saturated fat intake within both groups was observed following the intervention period (p < 0.05).

CONCLUSION:

Supplementation with C. fimbriata extract whilst controlling overall dietary intake and physical activity may potentially play a role in curbing central obesity, the key component of metabolic syndrome. Controlling dietary intake and exercise improved body weight and favourably influenced the metabolic risk profile.

> Antiobesogenic and Antiatherosclerotic Properties of Caralluma fimbriata Extract.

Source

Department of Animal Science, Bharathidasan University, Tiruchirappalli 620 024, India.

Abstract

There is evidence that the principles present in the widely consumed Indian food plant C. fimbriata extract (CFE) suppress appetite, and provide antiobesogenic and metabolic benefits. The Diet-Induced Obesity (DIO) rat model was used to investigate CFE's anorexigenic effects. Rats were randomly divided into three groups: (i) untreated control (C), (ii) control for cafeteria diet (CA), and (iii) cafeteria diet fed + CFE treated. Rats in the test group received cafeteria diet and CFE from day one onwards. CFE was administered by gavage at three doses (25, 50, 100 mg/Kg BW per day) for 90 days. The antiobesogenic effects of CFE were evaluated by monitoring changes in feed intake, body weight, serum lipid and hormonal (leptin) profiles, fat pads, and liver weight. Antiatherosclerotic effects were measured by histology. CFE induced significant and dose-dependent inhibition of food intake, with dose-related prevention of gains in body weight, liver weight, and fat pad mass. Alterations in serum lipid profiles associated with weight gain were similarly inhibited, as were the typical increases in serum leptin levels. These data substantiate CFE's reported anorexigenic effects. CFE treatment also conferred protection against atherogenesis. We conclude that CFE possesses antiobesogenic and antiatherosclerotic properties.

Side effects and safety of Caralluma Extract powder

Studies have shown that he is safe.

Safety Assessment of a Hydroethanolic Extract of Caralluma Fimbriata.

Source

Inc, Puyallup, WA, USA.

Abstract

This toxicological assessment evaluated the safety of a hydroethanolic extract prepared from Caralluma fimbriata (CFE), a dietary supplement marketed worldwide as an appetite suppressant. Studies included 2 in vitro genotoxicity assays, a repeated dose oral toxicity study, and a developmental study in rats. No evidence of in vitro mutagenicity or clastogenicity surfaced in the in vitro studies at concentrations up to 5000 μg of extract/plate (Ames test) or 5000 μg of extract/mL (chromosomal aberration test). No deaths or treatment-related toxicity were seen in the 6-month chronic oral toxicity study in Sprague-Dawley rats conducted at 3 doses (100, 300, and 1000 mg/kg body weight (bw)/d). The no observed effect level for CFE in this study was considered to be 1000 mg/kg bw/d. A prenatal developmental toxicity study conducted at 3 doses (250, 500, and 1000 mg/kg bw/d) in female Sprague-Dawley rats resulted in no treatment-related external, visceral, or skeletal fetal abnormalities, and no treatment-related maternal or pregnancy alterations were seen at and up to the maximum dose tested. CFE was not associated with any toxicity or adverse events.

Dosage of Caralluma Extract powder supplement:

Many Caralluma Extract powder supplements recommend a dosage of around 500 mg to 1000 mg.

Company Information:

Nutragreen Biotechnology Co., Ltd, a brand of Shanghai Lvshang Biotech Co., Ltd, is a GMP compliant and FDA registered manufacturer and supplier of raw materials of plant extracts, botanicals, herbs, especially Tradtional Chinese herbs. Caralluma Extract powder is one of our most competitive ingredients with various specifications and stocks available all year round. You may leave a message below for more detailed information.